Loading...
Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial
Gupta, V. Oh, S. Devos, T. Dubruille, V. Catalano, J. Somervaille, Tim C P Platzbecker, U. Giraldo, P. Kosugi, H. Sacha, T.
Gupta, V.
Oh, S.
Devos, T.
Dubruille, V.
Catalano, J.
Somervaille, Tim C P
Platzbecker, U.
Giraldo, P.
Kosugi, H.
Sacha, T.
Citations
Altmetric:
Abstract
A key hallmark of myelofibrosis is anemia, which ranges from mild to severe based on hemoglobin levels. To more clearly define outcomes with the Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor momelotinib by anemia severity, we performed a descriptive post hoc exploratory analysis of the double-blind, randomized, phase 3 SIMPLIFY-1 study (NCT01969838; N = 432, JAK inhibitor naive, momelotinib vs. ruxolitinib); subgroups were defined by baseline hemoglobin: <10 (moderate/severe), >= 10 to <12 (mild), or >= 12 g/dL (nonanemic). Spleen and symptom results were generally consistent with those previously reported for the intent-to-treat population. In anemic subgroups, momelotinib was associated with higher rates of transfusion independence and reduced/stable transfusion intensity vs. ruxolitinib. No new or unexpected safety signals were identified. Overall, momelotinib provides spleen, symptom, and anemia benefits to JAK inhibitor-naive patients with myelofibrosis regardless of baseline hemoglobin level, and greater anemia-related benefits vs. ruxolitinib in patients with hemoglobin <12 g/dL.
Description
Date
2024
Publisher
Collections
Files
Keywords
Type
Article
Citation
Gupta V, Oh S, Devos T, Dubruille V, Catalano J, Somervaille TCP, et al. Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial. LEUKEMIA & LYMPHOMA. 2024 2024 MAR 19. PubMed PMID: WOS:001187585300001. English.